CBHA

Histone deacetylase (HDAC) inhibitors hyperacetylate histones and increase transcriptional activity in selected genes. Importantly, HDAC inhibitors induce apoptosis in some cancer cells and show promise in the treatment of certain forms of cancer. CBHA is a potent HDAC inhibitor, exhibiting ID50 values of 0.01 and 0.07 µM in vitro for HDAC1 and HDAC3, respectively. CBHA also induces apoptosis in nine different neuroblastoma cell lines in culture (0.5-4.0 µM) and completely suppresses neuroblastoma tumor growth in SCID mice at 200 mg/kg. The efficacy of CBHA for suppressing tumor growth in mice is enhanced by the addition of retinoic acid.Formal Name: N-hydroxy-3-[3-(hydroxyamino)-3-oxo-1-propen-1-yl]-benzamide. CAS Number: 174664-65-4. Synonyms: Histone Deacetylase Inhibitor II, m-Carboxycinnamic Acid bis Hydroxamide. Molecular Formula: C10H10N2O4. Formula Weight: 222.2. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 20 mg/ml, DMSO: 25 mg/ml, DMSO:PBS (pH 7.2) (1:5): 0.15 mg/ml. lambdamax: 226, 271 nm. SMILES: ONC(=O)\C=C/c1cccc(c1)C(=O)NO. InChi Code: InChI=1S/C10H10N2O4/c13-9(11-15)5-4-7-2-1-3-8(6-7)10(14)12-16/h1-6,15-16H,(H,11,13)(H,12,14)/b5-4+. InChi Key: OYKBQNOPCSXWBL-SNAWJCMRSA-N.